Flash Therapeutics, a company involved in the design and bioproduction of lentiviral vectors for the transfer of DNA and RNA genetic material for customers in gene, cell, RNA and vaccine therapies, appointed Jérôme Bédier President. 

Bédier is an expert in the biomanufacturing and CDMO sector. With 25 years of experience, most particularly with the Novasep group, Jérôme Bédier held positions in business development and operations management before taking over strategic management of Novasep’s Biopharmaceutical business and its three European sites. Bedier deployed this investment program as Biopharma President. In 2021, Jérôme joined Cell-Easy as chief operating officer, where he oversaw the structuring and launch of CDMO activities in the field of cell therapy.

“We are delighted to welcome Jérôme Bédier, an expert in biomanufacturing and service to the biopharmaceutical industry, to the executive management of Flash Therapeutics,” said Jacques Rossignol, chairman of Flash Therapeutics’ supervisory board. “His expertise in the design and production of biotherapeutic products, and his perfect knowledge of markets and customers will be a considerable asset in accelerating Flash Therapeutics’ strategy in the biomanufacturing of DNA and RNA lentiviral solutions, by strengthening partnerships with the company’s existing customer portfolio and developing new ones.”

Bédier said, “I am very pleased to join Flash Therapeutics in Toulouse. France wishes to position itself as the spearhead of therapeutic biomanufacturing worldwide. Flash Therapeutics’ GMP capabilities and innovative technologies will be key in realizing this ambition, in a sector that is constantly evolving. We have a remarkable and unique lentiviral technology for the transfer of genetic material, both DNA and RNA. The exceptional efficiency of this technology is a concrete solution for our customers and their patients. With a new team and the support of our shareholders, we intend to strengthen our position as a global expert.”